Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2020-02-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于控股股东、实际控制人部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the release of pledged shares by a controlling shareholder. It details the number of shares released from pledge, the shareholder's total pledged shares, and confirms no risk of forced sale or change in control. The document is short (1360 characters) and focuses on share pledge status and shareholder information. It does not contain financial statements, earnings data, or management discussion. It is not an annual or interim report, nor an earnings release. It is a regulatory announcement about share pledge status, which fits best under Regulatory Filings (RNS) as it does not fit other more specific categories like Major Shareholding Notification (MRQ) or Transaction in Own Shares (POS) because it concerns pledge release, not share ownership change or buyback. Therefore, the classification is Regulatory Filings (RNS).
2020-02-27 Chinese
关于控股股东、实际控制人减持股份累计达到1%的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the cumulative reduction of shares held by the controlling shareholder and actual controller, Mr. Dong Fan, reaching 1%. It details the dates, quantities, and methods of share reduction, as well as the shareholder's holdings before and after the reduction. The document references compliance with relevant laws and regulations and confirms that the reduction will not affect control or governance. There is no financial report, earnings data, or management discussion. The content is focused on shareholding changes by a major shareholder, specifically the reduction of shares held by a controlling shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds such as 1%. The document length is 2270 characters, which is relatively short but contains detailed shareholding change information, not just a brief announcement or a certification. Therefore, the appropriate classification is MRQ with high confidence.
2020-02-24 Chinese
关于董事减持计划实施完毕的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a company director, specifically the Vice General Manager Zeng Kai. It details the number of shares reduced, the method of reduction, dates, and compliance with relevant securities laws and regulations. The document does not contain financial statements or performance data but focuses on insider share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short (1420 characters), and it is clearly an announcement of insider share transactions, not a financial report or other type of filing.
2020-02-20 Chinese
2019年度业绩快报
Interim / Quarterly Report Classification · 95% confidence The document is titled as a 2019 annual performance report (年度业绩快报) and contains detailed financial data for the full year 2019, including revenue, profit, net income, earnings per share, and asset information. It also includes a comprehensive explanation of business performance, marketing strategies, R&D, production, talent, brand building, and investment expansion. The document is 5586 characters long, which is sufficient to contain substantive financial data and analysis. It is not merely an announcement of a report or a certification. The content aligns with an Interim / Quarterly Report (IR) because it is a performance update for the year but is labeled as a performance quick report rather than a full Annual Report (10-K). However, given the detailed financial data and analysis for the full fiscal year, it is more consistent with an Interim / Quarterly Report (IR) rather than a full Annual Report (10-K), which would be more comprehensive and audited. The document explicitly states the data is preliminary and unaudited, which is typical for an interim or preliminary earnings report. Therefore, the best classification is Interim / Quarterly Report (IR). FY 2019
2020-02-05 Chinese
关于董事减持股份的预披露公告
Director's Dealing Classification · 100% confidence The document is a pre-disclosure announcement regarding a planned reduction of shares held by a company director, specifically the Vice General Manager Zeng Kai. It details the number of shares to be sold, the reasons for the sale, the method of sale, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report attached. The document is a notification of a director's personal share transaction (share reduction). This fits the definition of 'Director's Dealing' (DIRS). The document length is short and focused solely on the director's share reduction plan, confirming it is not a full report or announcement of a report publication.
2020-01-20 Chinese
关于使用闲置自有资金购买现金理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress of using idle funds to purchase cash management financial products. It details the amounts, counterparties, product types, expected yields, and risk management measures. The document references a shareholders' meeting resolution approving the use of funds for cash management and provides historical purchase details. It does not contain financial statements, earnings data, or detailed management analysis. The document is relatively short (3039 characters) and serves as an update on financing activities related to cash management products. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an annual or interim report, audit report, or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2020-01-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.